Breaking Finance News

Piper Jaffray upgraded Sangamo Therapeutics (NASDAQ:SGMO) from Neutral to Overweight in a report released today.

Piper Jaffray has upgraded Sangamo Therapeutics (NASDAQ:SGMO) from Neutral to Overweight in a report released on 11/15/2017.

Previously on 6/22/2017, Jefferies Group LLC reported about Sangamo Therapeutics (NASDAQ:SGMO) raised the target price from $0.00 to $17.00. At the time, this indicated a possible upside of 0.91%.

Yesterday Sangamo Therapeutics (NASDAQ:SGMO) traded 3.16% higher at $12.40. The company’s 50-day moving average is $14.54 and its 200-day moving average is $9.48. The last stock close price is up 46.29% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 618,101 shares of the stock were exchanged, down from an average trading volume of 1,643,800

See Chart Below

Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics has a 52 week low of $2.65 and a 52 week high of $17.06 Sangamo Therapeutics’s market capitalization is currently $0.

Brief Synopsis On Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.